Microarray-powered

Custom Monoclonal Antibody Development and Validation

Our antibody development platform addresses the urgent need for monoclonal antibodies with unprecedented specificity to native or denatured proteins.

REQUEST INFO

More Than 20,000+ Antigens Available

Using HuProt™ Human Proteome Microarray to validate the final product, your antibody is screened for cross-reactivity against the largest collection of human proteins on a single slide – representing approximately 75% of the human proteome.

CDI Labs' monoclonal antibody development, production and purification, along with HuProt™ microarray specificity validation, is (approximately) an 8-week process. It is a milestone-driven, 4-phase process with client reporting and assessment exchanged at each step. Invoicing begins at the initiation of Phase 1 and at the completion of each phase thereafter. Milestones represent potential endpoints that depend on your project requirements or if the results-to-date fail to meet your expectations.

Monospecificity in 8 Weeks

Our antibody development platform addresses the urgent need for monoclonal antibodies with unprecedented specificity to native or denatured proteins.

Quote

Project Specification

Antigen design, immunization strategy and screening methodology are critical to achieving high-value results. CDI Labs offers a fully-customized development process to meet the requirements and provide a quote based on deliverables.

Day 1

Phase 1
Antigen and Immunization

5-mouse immunization regimen using as little as 200 μg client-supplied protein of >80% purity or carrier-conjugated peptide. We also offer assistance in antigen design and synthesis.

Day 14

Phase 2
Fusion and Screening

2 top-responding animals are chosen, and immune cells are harvested for fusion with myeloma cells yielding multiple hybridomas. Supernatants from IgG-secreting clones are screened by ELISA.

Day 38

Phase 3
Sub-cloning, Expansion and Specificity Testing

A minimum of 5 to a maximum of 30 high-quality clones are chosen and sub-cloned. Each is expanded into 24-well plates and subsequently into T-25 flasks. Supernatants are shipped for further client evaluation.

Day 52

Phase 4
Production and Purification

Each clone is vialed, labeled and frozen. Samples of each are reserved for mycoplasma testing. Per client instructions, 3 select clones are placed into antibody production. The resulting antibodies are purified and evaluated with HuProt Human Proteome Microarray.

Day 56

Deliverables

Detailed specificity data and additional QA documentation are prepared and shipped along with the purified antibodies and all frozen clones.

Customer Testimonial

"We enjoyed working with CDI Labs. We used both VirScan and HuScan services from CDI Labs as part of our neurodegenerative disease research. The team at CDI Labs was very responsive and great to work with, and they went above and beyond to get us our results very quickly. They were particularly helpful in making contract arrangements and ensuring that everything was in place for a smooth collaboration. CDI Labs also provided a comprehensive statistical analysis, which will be invaluable as we build on our research. We’re still analyzing the data, but we’re confident that we’ll gain new insights into disease mechanisms that will advance our research."

Wouter Peelaerts, PhDProfessor, KU Leuven

Customer Testimonial

"CDI Labs provide consistent service and consistently high-quality protein array products to our lab. Their sales and scientific team are courteous and timely in their responses to our queries.”

Dr. Andrew McKeonMayo Clinic College of Medicine & Science

Data and technology validated by scientists

"We elected to use the HuProt Microarray because it is an extensive platform that contains over 21,000 unique, individually purified full-length human proteins and protein isoforms in duplicate, covering more than 81% of the proteome."

OncologistSchool of Medicine Research (as mentioned in "Baseline Serum Autoantibody Signatures Predict Recurrence and Toxicity in Melanoma Patients Receiving Adjuvant Immune Checkpoint Blockade" - AACR Clinical Caner Research - September 2022)

Data and technology validated by scientists

"This (VirScan) assay, which uses phage display immunoprecipitation and sequencing, is a sensitive and focused high-comprehensive approach that enables thorough serological profiling of antiviral antibodies in humans and, consequently, the identification of viral exposure throughout the human virome."

Faculty of MedicineResearch Institution (as mentioned in "Human virome profiling identified CMV as the major viral driver of a high accumulation of senescent CD8+ T cells in patients with advanced NSCLC" - Science Advances - November 2023)

Data and technology validated by scientists

"By using (HuProt) protein arrays, we were able to evaluate a broader range of antigens compared to previous investigations."

Senior ScientistBiotech Research (poster presentation at the San Antonio Breast Cancer Symposium 2023)